2 Minute Medicine: Pharma Roundup – Merck and Mayo Clinic’s AI precision medicine lab, Novartis’ remibrutinib hits Phase III hive endpoint, FDA grants priority review for iberdomide in myeloma, oral infigratinib boosts growth velocity in achondroplasia, and shingles vaccine/sildenafil linked to lower Alzheimer’s risk [February 2026]
Merck and Mayo Clinic launch AI-driven precision medicine partnership Merck and Mayo Clinic have officially kicked off a landmark R&D ...